Why the study?
Intravenous immunoglobulin combined with oral aspirin is first-line therapy to prevent coronary artery lesions in acute Kawasaki disease, but controversies persist regarding the role and optimal dose of aspirin.
What is the optimal dose, usage, and course of aspirin in the first-line treatment of Kawasaki disease in children?
What is the optimal dose, usage, and course of aspirin in the first-line treatment of Kawasaki disease in children?
This expert consensus provides updated recommendations on the optimal use of aspirin for the first-line treatment of Kawasaki disease in children in China.
Answers are grounded in this paper and cite their sources.
May guide aspirin dosing in pediatric Kawasaki disease; leaves open need for randomized validation.
Kawasaki disease (KD) is one of the common acquired heart diseases in children aged <5 years and is an acute systemic vasculitis. After nearly 60 years of research, intravenous immunoglobulin combined with oral aspirin has become the first-line treatment for the prevention of coronary artery lesion in acute KD; however, there are still controversies over the role and optimal dose of aspirin. The consensus was formulated based on the latest research findings of KD treatment in China and overseas and comprehensive discussion of pediatric experts in China and put forward recommendations on the dose, usage, and course of aspirin treatment in the first-line treatment of KD.
No takes yet. Share an insight, caveat, or question.
A 2022 study conducted a review in Kawasaki disease. Aspirin was evaluated. A pediatric expert consensus provides recommendations on the dose, usage, and course of aspirin for the first-line treatment of Kawasaki disease in children.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: